BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) said it has broadened the patent coverage for its viral vaccine platform by filing an international patent application through the Patent Cooperation Treaty (PCT) for BVX-1021, its vaccine for SARS1 and other sarbecoviruses.
The action further expands the value of its intellectual property (IP) portfolio, the company said.
BVX-1021 is the subject of an ongoing research collaboration between Ohio State University and BioVaxys that is evaluating the company's novel approach for a universal vaccine that can treat a broad range of sarbecoviruses. These are a family of viruses that include SARS-CoV-2 and emerging variants, SARS-CoV-1, and a broad range of other potentially dangerous zoonotic viruses.
READ: BioVaxys Technology adds experienced CFO Craig Loverock to its executive team
An international PCT application, which is a patent treaty with more than 150 member countries, makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single international patent application instead of filing several separate national or regional patent applications, BioVaxys noted.
This week, the company also filed multiple national phase patent applications for BVX-0320, its haptenized SARS-CoV-2 S1 subunit vaccine.
It is pursuing expanded patent protection in the major pharmaceutical markets of US, the European Union (including the UK and Turkey), Canada, China, Japan, Brazil, Israel, Egypt, and South Korea.
Vancouver-based BioVaxys is a British Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.
Contact the author at jon.hopkins@proactiveinvestors.com